ClinicalTrials.gg
Active, not recruitingNCT06464991FUMANBA-03Updated Nov 6, 2026

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

A Phase 3 interventional study of Equecabtagene Autoleucel Injection and Daratumumab in Multiple Myeloma, sponsored by Nanjing IASO Biotechnology Co., Ltd.. Active, not recruiting at 41 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Nanjing IASO Biotechnology Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Nov 6, 2026Now Active, not recruitingFirst site in Japan+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
49th of 406
260 · median 40
Started
2024
with 46 others
Phase 3
66 of 448
24 open now
Primary completion
2027-08
later than 158 of 274 live
Registered
303rd of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 49th largest by planned enrollment of the 406 interventional ones that give a count, is one of 47 that started in 2024, is one of 66 in phase 3, reaches primary completion later than 158 of the 274 other live ones, and was the 303rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomide-refractory relapsed/refractory multiple myeloma (RRMM) who have received 1-2 lines of prior therapy. Approximately 240 subjects from China and, in accordance with Japanese regulatory requirements, approximately 20 additional subjects from Japan are planned to be enrolled in this study, for a total of approximately 260 subjects.

Read the detailed description

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accounts for more than 10%-20% of hematologic malignancies worldwide, leading to marrow failure and bone destruction. Equecabtagene Autoleucel (eque-cel) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA), which expressed on both mature B lymphocytes and malignant plasma cells. The primary objective for this study is to compare the efficacy of eque-cel versus standard therapy in lenalidomid-refractory RRMM. Subjects will undergo screening with informed consent. After enrollment, randomization will be conducted followed by study treatment in experimental or control group. A follow-up phase will include assessments for safety, efficacy evaluation and pharmacokinetics monitoring (experimental arm) . The duration of this trial is about 6 years.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Eque-cel
  • BCMA CAR-T
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years of age (inclusive of critical values), either gender.
  2. The subject was previously diagnosed with multiple myeloma and had received 1-2 (including chemotherapy regimens based on proteasome inhibitors and immunomodulatory agents, with each line of therapy receiving at least 1 full cycle ; Documented disease progression during or within 12 months after the most recent anti-myeloma therapy.
  3. Subjects was lenalidomide- during prior therapy.
  4. score of 0 or 1.
  5. Subjects must have appropriate organ function and meet all of the following laboratory test results before enrollment:

(1) Haematology: (ANC) ≥1×10\^9/L (prior use of granulocyte colony-stimulating factor [G-CSF] support is permitted, but no supportive therapy have been received within 7 days before the laboratory test);Absolute lymphocyte count (ALC) ≥0.3×10\^9/L; ≥50×10\^9/L (must not have received platelet transfusion within 7 days prior to laboratory test); ≥60g/L (must not have received red blood cells transfusion within 7 days prior to laboratory test); (2) Hepatic function: (ALT) and aspartate aminotransferase (AST) ≤2.5 times of (ULN); Serum total ≤1.5 times of ULN; (3) Renal function: (CrCl) calculated by Cockcroft-Gault formula ≥ 40 ml/min; (4) Coagulation: fibrinogen≥1.0 g/L; (APTT) ≤ 1.5×ULN, pro-thrombin time (PT) ≤ 1.5 × ULN; (5) Pulse oxygen saturation > 91%; (6) (LVEF)≥50%;

6. Subjects agree to use effective tools or drug (excluding safe period contraception) after signing the form.

7. Subjects must agree to sign or personally sign an ethics committee-approved informed consent form before starting any screening procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have used or required long-term immune-suppressive agents (e.g., cyclosporine or systemic ) within 14 days prior to enrollment, but the use of physiological substitutes, intermittent, topical, and inhaled steroids is allowed.
  2. Subjects who have undergone haematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks prior to randomization, or who have previously undergone allogeneic haematopoietic stem cell transplantation (Allo-HSCT).
  3. Subjects received the following anti-tumor treatments before enrollment: (1)Treated with an immunomodulator within 7 days, or; (2)Received plasma exchange, radiotherapy (except local radiotherapy for myeloma-related bone lesions), cytotoxic chemotherapy, treatment with proteasome inhibitors or other drug within 14 days, or; (3) Treatment with monoclonal antibody for multiple myeloma within 21 days, or; (4) Received other anti-cancer therapy within 14 days or at least 5 half-lives (whichever is shorter) prior to enrollment.
  4. Significant cardiac disorder.
  5. Unstable systemic disease as judged by the investigator: including but not limited to severe liver, renal, or metabolic disease requiring medication.
  6. The subject will not be able to participate in this study if the investigator determines that the subject meets any of the following conditions: (1) Subjects with a history of allergic reaction to the components (DMSO and albumin) of Eque-cel, fludarabine, cyclophosphamide, tocilizumab, or; (2) Subjects who are intolerant to dexamethasone, or; (3) Subjects who have a Life-threatening allergy, reaction, or intolerance to pomalidomide and/or its excipients (intolerance is defined as discontinuation of prior treatment due to any AE related to pomalidomide) or;
  7. Have other than multiple myeloma within 5 years before screening, excluding cervical carcinoma in situ after radical surgery, basal cell or squamous cell skin cancer, localized cancer of prostate after radical prostatectomy, breast ductal carcinoma in situ after radical mastectomy or carcinoma papillary thyroid after radical thyroidectomy.
  8. Subjects suspected or confirmed to have central nervous system involvement of MM during the screening period.
  9. Subjects with concurrent plasma cell leukemia(defined as plasma cell proportion in peripheral blood > 5%), Waldenström macroglobulinaemia, POEMS syndrome (polyneuropathy, organ hypertrophy, endocrinopathy, monoclonal protein and skin changes) or primary amyloidosis during screening period.
  10. Patients with concomitant non-paraskeletal extramedullary soft tissue plasmacytoma (EM-E); patients with multiple paraskeletal extramedullary lesions (EM-B) where the longest diameter of the extramedullary part of any lesion is >3 cm; patients with a single paraskeletal extramedullary lesion (EMB) where the longest diameter of the extramedullary part is >5 cm;.
  11. Had major surgery within 2 weeks prior to randomization or planned to have surgery within 2 weeks after study treatment (except for subjects who were scheduled to have surgery under local anesthesia).
  12. Subject with uncontrollable infection.
  13. surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and hepatitis B virus (HBV) DNA quantification in peripheral blood was higher than the lower limit of detection; virus (HCV) antibody positive and hepatitis C virus (HCV) RNA positive in peripheral blood; (HIV) antibody positive; Syphilis test positive; positive cytomegalovirus (CMV) DNA.
  14. Pregnant or breastfeeding women.
  15. The subject has a history of central nervous system disorder within 6 months prior to signing the form.
  16. Non-hematological toxicity reactions due to prior treatment have not resolved to baseline or ≤ Grade 1 ( v5.0, alopecia, Grade 2 peripheral neuropathy were excepted).
  17. Subjects had other conditions that the investigator considered unsuitable for enrollment.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Drug:Equecabtagene Autoleucel Injection

    Drug: Equecabtagene Autoleucel Injection

  • Active comparator
    Control group

    Drug: Daratumumab, Bortezomib, Dexamethasone, Pomalidomide, DPd group: Daratumumab, Pomalidomide, Dexamethasone PVd group: Bortezomib, Dexamethasone, Pomalidomide

    Drug: Daratumumab · Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.

    Also known as: FUCASO

  • dosage form: injection or subcutaneous injection. For intravenous administration: dose level 16 mg/kg, 28 days/cycle for the DPd regimen * Cycle1-2: D1, D8, D15, D22; * Cycle3-6: D1, D15; * above Cycle7: D1; body weight should be recalculated on D1 of the current cycle if it differs from baseline by more than +/-10%. For subcutaneous administration: fixed dose of 1,800 mg. The formulation and route of administration (intravenous or subcutaneous) should be selected according to the clinical practice in the country where the study is conducted.

  • dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.

  • dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11; above cycle 9: D1, D8.

  • dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23; for PVd: Cycle1-8:D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.

06

What researchers measure

Primary outcomes

  1. Minimal Residual Disease (MRD)-negative complete response (CR) rate at 12 months

    The proportion of the first 126 randomized subjects who achieved a complete response (CR) or better, as assessed by Independent Review Committee (IRC), and were MRD-negative (assessed by next-generation flow cytometry \[NGF\] using the EuroFlow standard operating procedure) at 12 months (+/-3 months) post-randomization.

    Time frame: 12 months (+/-3 months) post-randomization

  2. Progression-Free Survival (PFS) as assessed by Independent Review Committee (IRC)

    The time from randomization to the first IRC-assessed disease progression or death from any cause.

    Time frame: up to 5 years from randomization

Secondary outcomes

  1. Overall MRD negativity rate

    The proportion of subjects who achieve MRD negativity at any time after the date of randomization and before the initiation of subsequent therapy

    Time frame: up to 5 years from randomization

  2. Duration of MRD negativity

    The time from first achievement of MRD negativity to the first subsequent positive MRD status

    Time frame: up to 5 years from randomization

  3. Complete Response Rate(CRR)

    The proportion of subjects who achieve CR or better post-randomization among all randomized subjects

    Time frame: up to 5 years from randomization

  4. Very good partial response or better response (≥VGPR) rate

    The proportion of subjects who achieve sCR, CR, or VGPR post-randomization among all randomized subjects

    Time frame: up to 5 years from randomization

  5. Overall Response Rate(ORR)

    The proportion of subjects who achieve sCR, CR, VGPR, or PR post-randomization among all randomized subjects.

    Time frame: up to 5 years from randomization

  6. Duration of Response (DOR)

    The time from the first date of initial documented response (≥PR) to the date of first disease progression or death from any cause, whichever occurs first, post-randomization

    Time frame: up to 5 years from randomization

  7. Event-Free Survival (EFS)

    Time from randomization to the first occurrence of any of the following events: death, disease progression, initiation of a new anti-myeloma therapy, addition of other treatments, or occurrence of fatal or intolerable adverse effects

    Time frame: up to 5 years from randomization

  8. Overall Survival(OS)

    Defined as the time from randomization to death due to any cause

    Time frame: up to 5 years from randomization

  9. Time to Next Treatment(TTNT)

    Time from randomization to the initiation of a new subsequent anti-myeloma therapies

    Time frame: up to 5 years from randomization

  10. Incidence of Adverse events

    Safety Endpoint

    Time frame: up to 5 years from randomization

  11. Pharmacokinetic Endpoint-Cmax

    The maximum concentration (Cmax) of CAR VCN and BCMA CAR-T in peripheral blood after CAR-T infusion

    Time frame: up to 5 years from Eque-cel infusion

  12. Pharmacokinetic Endpoint-Tmax

    the time for CAR VCN and BCMA CAR-T to reach the maximum concentration (Tmax) after CAR-T infusion

    Time frame: up to 5 years from Eque-cel infusion

  13. Pharmacokinetic Endpoint-AUC

    Area under the curve of 29, 85, 169 days and the last time point of PK detection (AUC0-29d, AUC0-85d, AUC0-169d, AUC0-last) for CAR VCN; Area under the curve of 29 days (AUC0-29) for BCMA CAR-T.

    Time frame: up to 5 years from Eque-cel infusion

  14. Pharmacodynamic Endpoint

    The concentration of soluble BCMA in peripheral blood of experimental group at each time point

    Time frame: up to 5 years from Eque-cel infusion

  15. Health Related Quality of Life Endpoint

    Symptoms, function, and overall HRQoL were collected using the validated Patient-Reported Outcomes (PRO) questionnaire

    Time frame: up to 5 years from randomization

07

Study locations

41 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Aug 2027, 41 months after the start.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 41 months is close to that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 18, 2024
StartActual
Mar 27, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Sites
15 sites added, 2 sites removed — first site in Japan
Show 15 added (13 Japan, 2 China)
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences · Tianjin, China
  • Tianjin Medical University General Hospital · Tianjin, China
  • Kyushu University Hospital · Fukuoka, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · Hiroshima, Japan
  • Hokkaido University Hospital · Hokkaido, Japan
  • Hyogo Medical University Hospital · Hyōgo, Japan
  • University Hospital, Kyoto Prefectural University of Medicine · Kyoto, Japan
  • Nagoya City University Hospital · Nagoya, Japan
  • Kindai University Hospital · Osaka, Japan
  • The University of Osaka Hospital · Osaka, Japan
  • Jichi Medical University Hospital · Tochigi, Japan
  • Institute of Science Tokyo Hospital · Tokyo, Japan
  • Japanese Red Cross Medical Center · Tokyo, Japan
  • Nihon University Itabashi Hospital · Tokyo, Japan
  • Tokyo Metropolitan Komagome Hospital · Tokyo, Japan
Show 2 removed
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences · Tianjing, China
  • Tianjin Medical University General Hospital · Tianjing, China
Nov 6, 2026
Enrollment
240→260
Nov 6, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedHaematology: absoluteAbsolute neutrophil count (ANC) ≥1×10\^9/L (support with growthprior use of granulocyte colony-stimulating factor [G-CSF] support is allowedpermitted, but must notno supportive therapy have been received supportive treatment within 7 days before the laboratory test); Absolute lymphocyte count (ALC) ≥0.3×10\^9/L; Platelets ≥50×10\^9 / L (must not have received platelet transfusion within 7 days prior to laboratory test); Hemoglobin ≥60g/L (must not have received red blood cells transfusion within 7 days prior to laboratory test); (2) Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times of upper limit of normal (ULN); Serum total bilirubin ≤1.5 times of ULN; (3) Renal function: creatinine clearance (CrCl) calculated by Cockcroft-Gault formula ≥ 40 ml/min; (4) Coagulation: fibrinogen≥1.0 g/L; activated partial thromboplastin time (APTT) ≤ 1.5×ULN, pro-thrombin time (PT) ≤ 1.5 × ULN; (5) Pulse oxygen saturation > 91%; (6) Left ventricular ejection fraction (LVEF)≥50%;
Exclusion criteria
  • EditedHavePatients with concomitant non-paraskeletal extramedullary multiple myeloma-extraosseoussoft tissue plasmacytoma (EM-E); havepatients with multiple paraskeletal extramedullary multiple myeloma-bone relatedlesions (EM-B) andwhere the maximum transverselongest diameter of the extramedullary part of any lesion is >3cm3 cm; havepatients with a single EM-B andparaskeletal extramedullary lesion (EMB) where the maximum transverselongest diameter of the lesionextramedullary part is >3cm5 cm;.
Nov 6, 2026
Primary outcomes
1 added, 1 description edited
What changed in the outcomes
  • AddedMinimal Residual Disease (MRD)-negative complete response (CR) rate at 12 monthsTime frame: 12 months (+/-3 months) post-randomization
  • DescriptionProgression-Free Survival (PFS) as assessed by Independent Review Committee (IRC): how it is measured was reworded
Nov 6, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedMinimal Residual Disease (MRD) negativity rate at 12 monthsTime frame: up to 5 years from randomization
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    15 sites added, 2 sites removed — first site in Japan
    Show 15 added (13 Japan, 2 China)
    • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences · Tianjin, China
    • Tianjin Medical University General Hospital · Tianjin, China
    • Kyushu University Hospital · Fukuoka, Japan
    • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · Hiroshima, Japan
    • Hokkaido University Hospital · Hokkaido, Japan
    • Hyogo Medical University Hospital · Hyōgo, Japan
    • University Hospital, Kyoto Prefectural University of Medicine · Kyoto, Japan
    • Nagoya City University Hospital · Nagoya, Japan
    • Kindai University Hospital · Osaka, Japan
    • The University of Osaka Hospital · Osaka, Japan
    • Jichi Medical University Hospital · Tochigi, Japan
    • Institute of Science Tokyo Hospital · Tokyo, Japan
    • Japanese Red Cross Medical Center · Tokyo, Japan
    • Nihon University Itabashi Hospital · Tokyo, Japan
    • Tokyo Metropolitan Komagome Hospital · Tokyo, Japan
    Show 2 removed
    • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences · Tianjing, China
    • Tianjin Medical University General Hospital · Tianjing, China
    Enrollment 240→260
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedHaematology: absoluteAbsolute neutrophil count (ANC) ≥1×10\^9/L (support with growthprior use of granulocyte colony-stimulating factor [G-CSF] support is allowedpermitted, but must notno supportive therapy have been received supportive treatment within 7 days before the laboratory test); Absolute lymphocyte count (ALC) ≥0.3×10\^9/L; Platelets ≥50×10\^9 / L (must not have received platelet transfusion within 7 days prior to laboratory test); Hemoglobin ≥60g/L (must not have received red blood cells transfusion within 7 days prior to laboratory test); (2) Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times of upper limit of normal (ULN); Serum total bilirubin ≤1.5 times of ULN; (3) Renal function: creatinine clearance (CrCl) calculated by Cockcroft-Gault formula ≥ 40 ml/min; (4) Coagulation: fibrinogen≥1.0 g/L; activated partial thromboplastin time (APTT) ≤ 1.5×ULN, pro-thrombin time (PT) ≤ 1.5 × ULN; (5) Pulse oxygen saturation > 91%; (6) Left ventricular ejection fraction (LVEF)≥50%;
    Exclusion criteria
    • EditedHavePatients with concomitant non-paraskeletal extramedullary multiple myeloma-extraosseoussoft tissue plasmacytoma (EM-E); havepatients with multiple paraskeletal extramedullary multiple myeloma-bone relatedlesions (EM-B) andwhere the maximum transverselongest diameter of the extramedullary part of any lesion is >3cm3 cm; havepatients with a single EM-B andparaskeletal extramedullary lesion (EMB) where the maximum transverselongest diameter of the lesionextramedullary part is >3cm5 cm;.
    Primary outcomes 1 added, 1 description edited
    What changed in the outcomes
    • AddedMinimal Residual Disease (MRD)-negative complete response (CR) rate at 12 monthsTime frame: 12 months (+/-3 months) post-randomization
    • DescriptionProgression-Free Survival (PFS) as assessed by Independent Review Committee (IRC): how it is measured was reworded
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedMinimal Residual Disease (MRD) negativity rate at 12 monthsTime frame: up to 5 years from randomization
    + 6 other changes: verification date, oversight details, description, conditions, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06464991
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Mar 27, 2024
Primary completion
Aug 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Gui Lu Qiu, PhD
principal investigator · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Zhen Cai, PhD
principal investigator · First Affiliated Hospital of Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Equecabtagene autoleucel

Start the discussion